New publication: quality of life of patients with SMA: a systematic review

Quality of life (QoL) is an important measure to help understand the clinical implications of a disease and inform optimum medical management, as well as to facilitate economic evaluations of new health technologies. As new therapies for spinal muscular atrophy (SMA) enter the market, it is increasingly important to establish measures of QoL in the different SMA types in order to have a baseline from which to assess treatment effect. This systematic review identified 15 relevant published studies out of 824 articles evaluated, covering 11 countries and three continents. Overall, while it was evident that SMA does affect QoL, in particular in the domain of physical health, there was a high level of variability between studies and between patient and caregiver responses. This makes it challenging to establish a standardised baseline, and little is known about the impact of the disease across different phenotypes, interventions and treatments.

Read the full publication at the journal website here.

Landfeldt E, Edström J, Sejersen T, Tulinius M, Lochmüller H, Kirschner J
Quality of life of patients with spinal muscular atrophy: a systematic review
European Journal of Paediatric Neurology
DOI: 10.1016/j.ejpn.2019.03.004

Abstract

Objectives

Senior author Jan Kirschner

To systematically review the literature of quality of life (QoL) of patients with spinal muscular atrophy (SMA), a rare, autosomal-recessive neuromuscular disease associated with extensive morbidity and elevated mortality.

Methods
We searched Embase, Web of Science, and PubMed for full-text, English-language articles (published between January 1, 2000 and July 31, 2018) reporting results from studies of QoL of patients with SMA. We excluded review and editorial articles, studies reporting results for samples comprising <5 patients (to allow for meaningful inference), and case reports/qualitative assessments.

Results
Of 824 identified articles, 15 met study criteria. Included publications contained data derived from samples from a total of 11 countries and three continents (Europe, North America, and South America). Estimates of the latent trait, primarily derived using the Pediatric Quality of Life Inventory (PedsQL) 4.0 Generic Core Scales and the PedsQL 3.0 Neuromuscular Module, indicated impairment in patient QoL, in particular physical functioning. However, both patient self- and caregiver proxy-assessments varied markedly across studies and subgroups. Among adult individuals, the mean self-assessed EuroQol-5D-3L utility has been estimated at 0.16 for a pooled sample of patients with SMA type I, II, and III, and −0.01 for SMA type II. Little is known of the impact of available treatments, including nusinersen, on patient QoL.

Conclusions
Our review shows that QoL is impaired in SMA, mainly due to compromised physical health, but also reveal that little is known of the impact of the disease across different phenotypes and clinical interventions.

Girl with SMA takes selfie with her brother

Read next...

New Publication: Congenital myasthenic syndrome with mild intellectual disability caused by a recurrent SLC25A1 variant

We were pleased to collaborate with colleagues in the UK, India, Germany, and Spain on this brief communication reporting three…

Conference Announcement: MITO2019 in Toronto 8-9th Nov

MITO2019 is the annual meeting for mitoNET and the MitoCanada Foundation and serves as the main education & networking event…

A new arrival accompanied by a new publication

The Lochmüller lab is pleased to welcome Dr. Emily O’Connor to the group in Ottawa. Emily marked her arrival in…

New Publication: Analysis of the functional capacity outcome measures for myotonic dystrophy

Being able to accurately and reliably asses functional capacity in people with myotonic dystrophy type 1 (DM1) is paramount to…

Foundation grant success for the Lochmüller Lab!

We are thrilled to announce that our Foundation Grant application on Precision Health for Neuromuscular Diseases (NMD) has been funded…

New publication: De-duplicating patient records from three independent data sources reveals the incidence of rare neuromuscular disorders in Germany

Patients with long-term, complex conditions like neuromuscular diseases may receive diagnosis, care and treatment in several different centres, each of…

New publication: Increasing phenotypic annotation improves the diagnostic rate of exome sequencing in a rare neuromuscular disorder

How can we use phenotypic descriptions to aid genetic diagnosis starting with hundreds of rare variants from next-generation sequencing results?…